logo
Share SHARE
FONT-SIZE Plus   Neg

Ipsen's Somatuline Gets Marketing Approval In Japan - Quick Facts

Ipsen (IPSEF.PK) said its partner Teijin obtained manufacturing and marketing approval from the Japan's Ministry of Health, Labour and Welfare for Somatuline 60/90/120 mg for s.c. injection (lanreotide acetate). In Japan, Somatuline is indicated for the treatment of growth hormone and IGF-I (somatomedin-C) hypersecretion and related symptoms in acromegaly and pituitary gigantism.

The company noted that Somatuline will be available in a new enhanced presentation with a pre-filled syringe that does not need reconstitution and with a retractable needle that improves safety for caregivers.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ford Motor Co.(F) reported a profit for the second-quarter that declined 8.8 percent from last year, while total revenue increased about 6 percent. The company now sees risks challenging achieving 2016 guidance. ConocoPhillips on Thursday reported a loss for the second quarter that widened from last year, reflecting lower revenues and one-time charges. The results for the quarter missed analysts' estimates. However, the company raised its production outlook for the full-year. Like other companies in the oil industry, ConocoPhillips is struggling with lower oil prices. Bristol-Myers Squibb Co. on Thursday raised its earnings forecast for fiscal 2016 after reporting a significant profit in its second quarter, compared to prior year's loss. The results reflected the absence of prior year's hectic charge as well as strong revenue growth. Earnings per share and top line beat market estimates.
comments powered by Disqus
Follow RTT